USPTO issues patent to KAHR-101 for treatment of cancers, arthritis and MS

Published on February 5, 2013 at 1:37 AM · 1 Comment

Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that its portfolio company, KAHR Medical Ltd. ("KAHR"), was granted a U.S. patent approval (U.S. Patent No. 8329657).  

This patent approval follows other patents already received in the U.S., Europe, Japan and Israel, protecting different combinations of KAHR's 'Signal Converting Proteins (SCPs)', which are bi-functional chimeric proteins with synergistic effects that improve the efficiency of pharmaceutical treatments. The newly issued patent protects one of KAHR's products in development, KAHR-101, which has been shown to be effective in the treatment of various cancers, arthritis and multiple sclerosis in animal models.

Ophir Shahaf , CEO of Hadasit Bio-Holdings, stated, "KAHR Medical develops ground-breaking products and we are constantly working to strengthen the company's intellectual property. The company uses a novel technology by which two therapeutic pathways can be simultaneously stimulated by a single protein drug in a synergistic manner, optimizing the care provided to patients. The completion of a recent fundraising round a few months ago will allow for further development and advancement of KAHR's drugs. We believe that in the coming year our portfolio companies will continue to present considerable clinical and business developments increasing their value as well as ours."

Source:

Hadasit Bio-Holdings Ltd.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
  1. Mark Waller Mark Waller United States says:

    I find it rather interesting that at the end of most of these articles it shows the source of the information as being the very company that has happened along some new great science.  Shouldn't there also be a link to the website where you can now purchase stock in that company?  Is there any third party independent reporting of these findings?

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Research on inflammasomes lays foundations for developing new RA treatments